These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

334 related articles for article (PubMed ID: 29668918)

  • 1. Glutamatergic Signaling Drives Ketamine-Mediated Response in Depression: Evidence from Dynamic Causal Modeling.
    Gilbert JR; Yarrington JS; Wills KE; Nugent AC; Zarate CA
    Int J Neuropsychopharmacol; 2018 Aug; 21(8):740-747. PubMed ID: 29668918
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ketamine and Attentional Bias Toward Emotional Faces: Dynamic Causal Modeling of Magnetoencephalographic Connectivity in Treatment-Resistant Depression.
    Gilbert JR; Galiano CS; Nugent AC; Zarate CA
    Front Psychiatry; 2021; 12():673159. PubMed ID: 34220581
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparing the actions of lanicemine and ketamine in depression: key role of the anterior cingulate.
    Downey D; Dutta A; McKie S; Dawson GR; Dourish CT; Craig K; Smith MA; McCarthy DJ; Harmer CJ; Goodwin GM; Williams S; Deakin JF
    Eur Neuropsychopharmacol; 2016 Jun; 26(6):994-1003. PubMed ID: 27133029
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synaptic potentiation is critical for rapid antidepressant response to ketamine in treatment-resistant major depression.
    Cornwell BR; Salvadore G; Furey M; Marquardt CA; Brutsche NE; Grillon C; Zarate CA
    Biol Psychiatry; 2012 Oct; 72(7):555-61. PubMed ID: 22521148
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
    Zarate CA; Singh JB; Carlson PJ; Brutsche NE; Ameli R; Luckenbaugh DA; Charney DS; Manji HK
    Arch Gen Psychiatry; 2006 Aug; 63(8):856-64. PubMed ID: 16894061
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neurophysiological Changes Associated with Antidepressant Response to Ketamine Not Observed in a Negative Trial of Scopolamine in Major Depressive Disorder.
    Park L; Furey M; Nugent AC; Farmer C; Ellis J; Szczepanik J; Lener MS; Zarate CA
    Int J Neuropsychopharmacol; 2019 Jan; 22(1):10-18. PubMed ID: 30184133
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
    Murrough JW; Iosifescu DV; Chang LC; Al Jurdi RK; Green CE; Perez AM; Iqbal S; Pillemer S; Foulkes A; Shah A; Charney DS; Mathew SJ
    Am J Psychiatry; 2013 Oct; 170(10):1134-42. PubMed ID: 23982301
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ketamine Enhances Visual Sensory Evoked Potential Long-term Potentiation in Patients With Major Depressive Disorder.
    Sumner RL; McMillan R; Spriggs MJ; Campbell D; Malpas G; Maxwell E; Deng C; Hay J; Ponton R; Kirk IJ; Sundram F; Muthukumaraswamy SD
    Biol Psychiatry Cogn Neurosci Neuroimaging; 2020 Jan; 5(1):45-55. PubMed ID: 31495712
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of ketamine on circadian rhythm and synaptic homeostasis in patients with treatment-resistant depression: A protocol for mechanistic studies of its rapid and sustained antidepressant actions in humans.
    Zhuo C; Tian H; Li G; Chen M; Jiang D; Lin X; Xu Y; Wang W
    Brain Behav; 2019 Nov; 9(11):e01423. PubMed ID: 31617335
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Single-dose infusion ketamine and non-ketamine N-methyl-d-aspartate receptor antagonists for unipolar and bipolar depression: a meta-analysis of efficacy, safety and time trajectories.
    Kishimoto T; Chawla JM; Hagi K; Zarate CA; Kane JM; Bauer M; Correll CU
    Psychol Med; 2016 May; 46(7):1459-72. PubMed ID: 26867988
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized controlled trial of intranasal ketamine in major depressive disorder.
    Lapidus KA; Levitch CF; Perez AM; Brallier JW; Parides MK; Soleimani L; Feder A; Iosifescu DV; Charney DS; Murrough JW
    Biol Psychiatry; 2014 Dec; 76(12):970-6. PubMed ID: 24821196
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Symptomatology and predictors of antidepressant efficacy in extended responders to a single ketamine infusion.
    Pennybaker SJ; Niciu MJ; Luckenbaugh DA; Zarate CA
    J Affect Disord; 2017 Jan; 208():560-566. PubMed ID: 27839782
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Default Mode Connectivity in Major Depressive Disorder Measured Up to 10 Days After Ketamine Administration.
    Evans JW; Szczepanik J; Brutsché N; Park LT; Nugent AC; Zarate CA
    Biol Psychiatry; 2018 Oct; 84(8):582-590. PubMed ID: 29580569
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-D-aspartate antagonist, CP-101,606, in patients with treatment-refractory major depressive disorder.
    Preskorn SH; Baker B; Kolluri S; Menniti FS; Krams M; Landen JW
    J Clin Psychopharmacol; 2008 Dec; 28(6):631-7. PubMed ID: 19011431
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of subanesthetic doses of ketamine on AMPA-mediated responses in rats: An in vivo electrophysiological study on monoaminergic and glutamatergic neurons.
    El Iskandrani KS; Oosterhof CA; El Mansari M; Blier P
    J Psychopharmacol; 2015 Jul; 29(7):792-801. PubMed ID: 25759403
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effects of low-dose ketamine on the prefrontal cortex and amygdala in treatment-resistant depression: A randomized controlled study.
    Li CT; Chen MH; Lin WC; Hong CJ; Yang BH; Liu RS; Tu PC; Su TP
    Hum Brain Mapp; 2016 Mar; 37(3):1080-90. PubMed ID: 26821769
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ketamine improves short-term plasticity in depression by enhancing sensitivity to prediction errors.
    Sumner RL; McMillan R; Spriggs MJ; Campbell D; Malpas G; Maxwell E; Deng C; Hay J; Ponton R; Sundram F; Muthukumaraswamy SD
    Eur Neuropsychopharmacol; 2020 Sep; 38():73-85. PubMed ID: 32763021
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evidence that Subanesthetic Doses of Ketamine Cause Sustained Disruptions of NMDA and AMPA-Mediated Frontoparietal Connectivity in Humans.
    Muthukumaraswamy SD; Shaw AD; Jackson LE; Hall J; Moran R; Saxena N
    J Neurosci; 2015 Aug; 35(33):11694-706. PubMed ID: 26290246
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Family history of alcohol dependence and antidepressant response to an N-methyl-D-aspartate antagonist in bipolar depression.
    Luckenbaugh DA; Ibrahim L; Brutsche N; Franco-Chaves J; Mathews D; Marquardt CA; Cassarly C; Zarate CA
    Bipolar Disord; 2012 Dec; 14(8):880-7. PubMed ID: 22978511
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Disentangling the association of depression on the anti-fatigue effects of ketamine.
    Saligan LN; Farmer C; Ballard ED; Kadriu B; Zarate CA
    J Affect Disord; 2019 Feb; 244():42-45. PubMed ID: 30312839
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.